Evaluate the PK Efficacy Safety and Tolerability of Pegcetacoplan in Patients With Thrombotic Microangiopathy

PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

February 1, 2022

Primary Completion Date

November 25, 2024

Study Completion Date

November 25, 2024

Conditions
Transplant-Associated Thrombotic Microangiopathy
Interventions
DRUG

Pegcetacoplan

20-cc glass vials-1080 mg

Trial Locations (14)

10676

"General Hospital of Athens Evangelismos", Athens

12462

"University General Hospital Attikon", Athens

20162

Big Metropolitan Hospital Niguarda Regional Health Authority, Milan

20900

ASST Monza - S. Gerardo Hospital, Monza

28222

University Hospital Puerta de Hierro Majadahonda, Madrid

42270

CHU de Saint-Etienne, Saint-Priest-en-Jarez

55905

Mayo Clinic - Rochester, Rochester

57010

"General Hospital of Thessaloniki G. Papanikolaou, Hematology Department - BMT Unit", Thessaloniki

75010

Saint-Louis Hospital, Paris

83100

Hospital San Giuseppe Moscati, Avellino

91010

City of Hope, Duarte

900146

United Hospitals Villa Sofia Cervello, Palermo

06202

Archet 1 hospital, Department of Clinical Hematology, Nice

00168

"University Polyclinic Foundation Agostino Gemelli - IRCCS", Roma

Sponsors
All Listed Sponsors
collaborator

Apellis Pharmaceuticals, Inc.

INDUSTRY

lead

Swedish Orphan Biovitrum

INDUSTRY